MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

BLCO — Bausch + Lomb Corporation

NYSE

Bausch + Lomb Corporation

CompareBack to Screener
$17.11
+0.17(+1.00%)
O
17.13
H
17.16
L
16.80
V
348.08K
⏱️ End-of-day dataAs of Oct 2, 2026

Chart

About BLCO

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

IndustryOPHTHALMIC GOODS
SectorNot available
IPO DateMay 6, 2022
Employees13,000
Stock ExchangeNYSE
Ticker SymbolBLCO

Key Financial Statistics

Market Cap$6.02B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$13.77 - $18.92
52-Week Avg Volume420.9K
VWAP$17.05
Transactions5,238
Total Recorded Bars4,134 days